Uncategorized
Ralinepag Demonstrates Transformative 55% Risk Reduction in PAH, Challenging Oral Selexipag Dominance
Phase 3 ADVANCE OUTCOMES data establishes ralinepag as a highly potent, once-daily prostacyclin receptor agonist, delivering unparalleled functional recovery metrics despite classic pathway tolerability hurdles. See Disclaimer below * Pulmonary Arterial Hypertension (PAH) represents a progressive, highly fatal orphan disease characterized by severe right ventricular failure. The United States accounts for